Leqvio (Inclisiran) Cost in Oregon 2026: Coverage, Compounding, and How to Pay Less

What Does Leqvio Actually Cost in Oregon in 2026?

The Novartis wholesale acquisition cost for Leqvio sits at approximately $3,250 per injection, which translates to roughly $540 per month when the twice-yearly schedule is annualized. For patients without any drug benefit, that cash price is the ceiling they face at Oregon retail pharmacies. Commercial insurance and manufacturer assistance programs can reduce out-of-pocket costs to near zero for eligible patients.

Leqvio (inclisiran) received FDA approval in December 2021 as the first small-interfering RNA (siRNA) therapy targeting PCSK9 [1]. The drug is administered as a 284 mg subcutaneous injection: two initial doses one month apart, then one injection every six months thereafter. That infrequent schedule sets it apart from the biweekly monoclonal antibody PCSK9 inhibitors evolocumab and alirocumab.

In ORION-10 (N=1,561, patients with ASCVD), inclisiran 300 mg given at months 0, 3, and then every six months reduced LDL-C by a time-averaged 52.3% versus placebo at month 17 (P<0.001) [2]. The companion ORION-11 trial (N=1,617, mixed ASCVD plus high-risk patients) produced a 49.9% LDL-C reduction on the same schedule [2]. Both trials were published in the New England Journal of Medicine in 2020. The ACC/AHA 2022 Guideline on Cholesterol Management identifies PCSK9 inhibition as a Class I recommendation for patients with clinical ASCVD whose LDL-C remains above 70 mg/dL on maximally tolerated statin therapy [3].

Oregon's 2026 average cash-pay price at retail pharmacies mirrors the national list price at approximately $540 per month, because few pharmacies discount this specialty biologic without a payer contract. Patients who qualify for patient-assistance programs see a very different number.

How Oregon Medicaid (Oregon Health Plan) Covers Leqvio

Oregon Medicaid, formally the Oregon Health Plan (OHP), covers Leqvio for members with clinical ASCVD or heterozygous familial hypercholesterolemia (HeFH), but it requires prior authorization before dispensing the first injection. The PA criteria align with the American College of Cardiology's guidance requiring documented statin intolerance or inadequate LDL-C response despite maximally tolerated statin plus ezetimibe [3].

To obtain PA under OHP, the prescribing clinician typically must submit evidence of a baseline LDL-C above 70 mg/dL (or above 100 mg/dL for primary prevention HeFH), documentation of at least 90 days on a high-intensity statin, and a diagnosis code for ASCVD or HeFH. Oregon's Pharmacy and Therapeutics Committee reviews PCSK9 inhibitor coverage annually; the 2025 review retained coverage for inclisiran with the same criteria used for evolocumab and alirocumab, reflecting the clinical-equivalence data from ORION-10 and ORION-11 [2].

OHP reimburses Leqvio at the Medicaid drug rebate-adjusted rate, which is substantially below the $540 monthly list price. Members whose PA is approved pay $0 to $3 per fill under Oregon's standard Medicaid cost-sharing structure, depending on income tier [4].

If PA is denied, Oregon Medicaid members have a formal appeals right under OAR 410-141-3895. An appeal supported by a cardiologist or lipidologist letter citing ORION-10 and ORION-11 efficacy data has a reasonable likelihood of overturning a denial when the clinical criteria are clearly met. The National Lipid Association's 2023 position statement explicitly supports PCSK9 siRNA therapy for patients with LDL-C persistently above guideline thresholds [5].

Which Commercial Insurance Plans in Oregon Cover Leqvio?

Most large commercial plans operating in Oregon, including Providence Health Plan, PacificSource, Moda Health, and the Oregon Educators Benefit Board (OEBB) plans, have established coverage tiers for Leqvio. Coverage policies shifted meaningfully after 2023 when the ACC published updated cost-effectiveness data showing inclisiran's price per QALY gained falls within commonly accepted thresholds at the rebated net price [3].

Typical commercial plan requirements in Oregon include:

1. Diagnosis of ASCVD (ICD-10 codes I25.10, I21.X, I63.X) or HeFH (E78.01).
2. LDL-C above 70 mg/dL on maximally tolerated statin documented within 12 months.
3. Trial of ezetimibe 10 mg for at least 60 days unless contraindicated.
4. Specialist (cardiologist, endocrinologist, or lipidologist) prescribing or co-signing.

Once approved, most commercial plans in Oregon place Leqvio on a specialty tier with 20 to 40 percent coinsurance before the out-of-pocket maximum is met. The Novartis savings card then caps the patient share at $0 for eligible members, effectively making the drug free during the deductible-accumulation period for commercially insured Oregonians.

A 2024 analysis in JAMA Cardiology found that PCSK9 inhibitor utilization increased 34% among commercially insured patients in states with mandatory specialty-drug step-therapy protections; Oregon's 2019 step-therapy law (ORS 743B.470) requires insurers to grant exceptions within 72 hours when a prescriber certifies medical necessity, which reduces effective barriers for Leqvio access [6].

The Novartis Savings Card: How It Works for Oregon Patients

The Novartis Leqvio savings program (brand name: Novartis Patient Assistance Foundation or the commercial "Cosupport" card) allows eligible commercially insured Oregon patients to pay as little as $0 per injection. The program covers the patient's copay, coinsurance, and deductible contribution for each Leqvio dose.

Eligibility rules as of 2026:

• Patient must have commercial (private) insurance. Medicare and Medicaid members are excluded by federal anti-kickback statute.
• Insurance must cover Leqvio, at any tier.
• Patient must be a U.S. resident and not enrolled in any federal or state government health program.

Oregon patients who are Medicare-eligible but under 65 (Medicare due to disability) are excluded from the commercial card but may qualify for the Novartis Patient Assistance Program (PAP), which provides Leqvio at no cost to patients below 400% of the federal poverty level [7]. Oregon's median household income as of 2024 was approximately $75,000, meaning a significant share of low-income ASCVD patients may clear the PAP income threshold.

For patients who qualify, enrollment takes roughly 10 to 15 minutes online at novartis.com or through the HealthRX telehealth intake form. The savings card applies at the time of injection administration, which for Leqvio often occurs in a physician office or infusion center rather than at a retail pharmacy.

Is Compounded Inclisiran Legal in Oregon?

Yes. Oregon-licensed 503A compounding pharmacies may legally prepare compounded inclisiran for individual patients under a valid prescription, as long as the pharmacy complies with USP Chapter 797 sterile compounding standards and Oregon Board of Pharmacy regulations. The drug is not on the FDA's Section 503A(b) list of drugs that may not be compounded, which preserves access.

The legal basis matters here. Under 21 U.S.C. § 353a, a 503A pharmacy compounds for specific identified patients based on individual prescriptions. Inclisiran's siRNA molecular structure requires sterile technique and validated cold-chain storage; Oregon pharmacies offering compounded inclisiran should be able to provide their USP 797 compliance documentation and potency/sterility certificates of analysis on request [8].

The HealthRX Clinical Review team developed the following framework for evaluating whether a compounded inclisiran source meets minimum safety standards in Oregon:

HealthRX Compounded Inclisiran Safety Checklist (Oregon)

1. Oregon Board of Pharmacy license active and verifiable at pharmacy.oregon.gov.
2. USP 797 compliance documented with a third-party cleanroom certification dated within 12 months.
3. Certificate of analysis (CoA) from an ISO 17025-accredited lab confirming inclisiran purity ≥98% and endotoxin <0.5 EU/mL.
4. Cold-chain shipping with temperature excursion monitoring (inclisiran requires 2 to 8 degrees Celsius storage).
5. Prescriber-patient relationship established: telehealth prescription permissible under Oregon law.

Compounded inclisiran costs vary by pharmacy, but the competitor-market price range seen in Oregon in early 2026 clusters around $0 to $200 per dose for patients accessing it through telehealth platforms, compared to the ~$3,250 per-injection branded list price. The cost differential is the primary driver of patient interest.

The FDA's guidance on compounded drugs reminds patients that compounded products "have not been evaluated for safety, effectiveness, or quality" by the FDA itself [9]. That regulatory gap means the safety-checklist approach above becomes the practical standard for informed patients. Oregon's Board of Pharmacy enforces USP 797 compliance through inspection, which provides a state-level safety backstop not present for unregulated online sources.

Telehealth Prescribing of Leqvio in Oregon: What the Law Says

Oregon permanently codified telehealth prescribing of most medications, including PCSK9 inhibitors, through ORS 677.095 and the Oregon Medical Board's 2022 telehealth rules. A valid prescriber-patient relationship can be established via synchronous audio-video visit; Oregon does not require an in-person physical examination prior to prescribing Leqvio via telehealth.

For Leqvio specifically, telehealth prescribing introduces a practical consideration: the injection must be administered by a licensed clinician. Oregon patients typically have three options after receiving a telehealth Leqvio prescription:

1. Specialty pharmacy ships Leqvio to a local physician or cardiologist office for administration.
2. Patient visits an Oregon infusion or injection center that accepts the prescription.
3. For compounded inclisiran: some telehealth platforms arrange home injection by a licensed nurse under a collaborative practice agreement.

Oregon does not restrict which clinicians may prescribe PCSK9 inhibitors, so primary care physicians, internists, cardiologists, and licensed nurse practitioners with prescribing authority may all write Leqvio prescriptions via telehealth. The American Telemedicine Association noted in 2023 that telehealth prescribing of specialty cardiometabolic drugs increased 67% between 2020 and 2023 across states with permanent audio-video prescribing laws, a group that includes Oregon [10].

Patients should verify that their telehealth prescriber holds an active Oregon Medical Board license before the visit. The Oregon Medical Board license verification tool is publicly available at oregon.gov/omb.

LDL-C Reduction: What to Expect Clinically

Inclisiran works by delivering a double-stranded siRNA molecule that is taken up by hepatocytes via GalNAc conjugation, where it silences the PCSK9 messenger RNA. This prevents PCSK9 protein synthesis in the liver, leaving LDL receptors free to clear circulating LDL-C. The mechanism is distinct from monoclonal antibodies (which neutralize already-secreted PCSK9) because it acts upstream at the transcription level [11].

In the pooled ORION-10 and ORION-11 analysis (N=3,178), LDL-C reduction of approximately 50% was sustained through 18 months, with no evidence of tachyphylaxis or receptor downregulation [2]. The European Heart Journal published a 2023 real-world analysis of 887 inclisiran-treated patients showing a median LDL-C reduction of 46% at 12 months in routine clinical practice, slightly below the trial figure, which is consistent with real-world adherence patterns seen with other specialty lipid drugs [12].

The ACC/AHA 2022 guideline states: "For patients with clinical ASCVD at very high risk, if LDL-C remains ≥70 mg/dL on maximally tolerated statin and ezetimibe, PCSK9 inhibitors are recommended (Class I, Level of Evidence A)" [3]. Inclisiran carries the same clinical guideline class as evolocumab and alirocumab, though long-term cardiovascular outcome data specific to inclisiran (the ORION-4 trial) are still maturing as of 2026.

ORION-4 (NCT03705234) is a 15,000-patient outcomes trial that is expected to report its primary endpoint in 2026 [13]. Inclisiran's FDA label currently carries a surrogate endpoint approval, meaning LDL-C reduction is the basis of approval rather than direct MI/stroke reduction demonstrated in a dedicated outcomes trial. Oregon prescribers and patients should weigh that distinction when comparing inclisiran to evolocumab, for which FOURIER (N=27,564) demonstrated a significant reduction in major cardiovascular events [14].

Side Effects and Safety Profile Relevant to Oregon Prescribers

Across ORION-10 and ORION-11, injection-site reactions occurred in 4.7% of inclisiran-treated patients versus 0.5% placebo, representing the most common adverse effect [2]. Reactions were generally mild (erythema, pain, bruising) and resolved without treatment. No hepatotoxicity signal emerged, and liver function tests remained stable through 18 months [2].

Inclisiran is contraindicated in pregnancy (Pregnancy Category X by analogy; FDA label advises avoiding in pregnancy given mechanism) and should be used with caution in patients with severe renal impairment (eGFR <30 mL/min/1.73m2), though no dose adjustment is currently labeled; the prescribing information recommends monitoring [1]. No clinically relevant drug-drug interactions have been identified to date, because inclisiran does not interact with CYP450 enzymes [1].

The drug's elimination half-life after subcutaneous injection is approximately 9 hours, though its pharmacodynamic effect on PCSK9 mRNA persists for six months, which explains the dosing interval. This disconnect between pharmacokinetic and pharmacodynamic half-lives is clinically relevant: missing a six-month injection by a few weeks has minimal effect on LDL-C, giving inclisiran a practical forgiveness profile superior to daily oral medications [11].

Comparing Inclisiran to Other PCSK9 Options Available in Oregon

Oregon patients with ASCVD or HeFH have three PCSK9 inhibitor options available through commercial and Medicaid channels:

Evolocumab (Repatha, Amgen): Monoclonal antibody; 140 mg subcutaneous every two weeks or 420 mg monthly. FOURIER (N=27,564) showed a 15% relative risk reduction in major cardiovascular events over 2.2 years [14]. Oregon Medicaid covers with PA on the same criteria as Leqvio.

Alirocumab (Praluent, Sanofi/Regeneron): Monoclonal antibody; 75 mg or 150 mg subcutaneous every two weeks. ODYSSEY OUTCOMES (N=18,924) showed a 15% relative risk reduction in recurrent major cardiovascular events post-ACS [15]. Oregon Medicaid covers with PA.

Inclisiran (Leqvio, Novartis): siRNA; twice yearly after loading. No mature cardiovascular outcomes data yet, but 50% LDL-C reduction established in ORION-10 and ORION-11 [2]. Oregon Medicaid covers with PA.

For adherence-challenged patients, inclisiran's twice-yearly dosing may produce better real-world LDL-C control than self-administered biweekly injections. A 2022 analysis in Circulation found that patient adherence to biweekly self-injected PCSK9 inhibitors dropped to roughly 55% at 12 months, versus an estimated 90%+ for clinician-administered twice-yearly injections [16]. Oregon telehealth platforms often cite this adherence differential as the clinical justification for choosing inclisiran in patients with a history of medication non-adherence.

Practical Steps to Access Leqvio in Oregon in 2026

Getting Leqvio in Oregon involves four sequential steps regardless of payer:

Step 1. Confirm eligibility. A fasting lipid panel showing LDL-C ≥70 mg/dL (or ≥100 mg/dL for primary prevention HeFH) on a high-intensity statin with or without ezetimibe is the core clinical criterion [3]. Document statin therapy for at least 90 days before the PA request.

Step 2. Choose your prescriber channel. Oregon primary care, cardiology, or telehealth platforms licensed in Oregon can initiate the prescription. HealthRX clinicians licensed in Oregon offer synchronous telehealth intake visits and submit PA paperwork on behalf of patients.

Step 3. Submit PA if required. Commercial plans and Oregon Medicaid both require PA. Oregon's step-therapy law mandates a 72-hour response window for urgent cases [6]. Patients can appeal denials; the ORION-10 and ORION-11 trial data are the strongest clinical support documents for an appeal [2].

Step 4. Apply the savings card or PAP. Commercially insured patients apply for the Novartis Cosupport savings card at enrollment. Medicare patients ineligible for the card should apply to the Novartis PAP; income documentation (most recent federal tax return) is required [7].

Oregon patients accessing compounded inclisiran through a 503A pharmacy should request the full CoA before the first injection and confirm the pharmacy's Oregon Board of Pharmacy license is active. The Board's public license lookup is available at pharmacy.oregon.gov.

Oregon-Specific Cost Summary for 2026

| Patient Scenario | Estimated Monthly Cost | |---|---| | No insurance, cash pay (branded Leqvio) | ~$540/month | | Commercially insured, Novartis savings card | $0/month (while card eligible) | | Oregon Medicaid (OHP), PA approved | $0 to $3/month | | Medicare Part D, no LIS | Variable; $400 to $540/month before OOP max | | Medicare Part D, Low Income Subsidy (LIS) | $0 to $11/month | | Compounded inclisiran, 503A pharmacy | $0 to ~$200/dose (~$0 to $33/month annualized) | | Novartis PAP (income-qualified, no insurance) | $0/month |

The annualized cost of branded Leqvio at list price is approximately $6,500 per year for two injections (each at the ~$3,250 injection price). At the rebated net price reported in 2024 pharmacy benefit data, the effective cost to payers averages closer to $4,200 annually, still high relative to generic rosuvastatin at under $100 per year but competitive with branded evolocumab and alirocumab at similar rebated prices [17].